Guardant Health Expands Shield CRC Screening Coverage
PALO ALTO, Calif., Sept. 1, 2026 Guardant Health announced that its Shield blood test for colorectal cancer (CRC) screening...
Cancer Screening
Advertisement
Guardant Health Launches Patrick Dempsey Campaign for CRC Screening
PALO ALTO, Calif., July 28, 2026 Guardant Health, Inc. has launched a new colorectal cancer (CRC) awareness campaign featuring...
GRAIL Teams with Priority Health to Expand Galleri
MENLO PARK, Calif., July 16, 2026 GRAIL, Inc. has announced a strategic collaboration with Priority Health, making the Galleri®...
Freenome Reports Strong SimpleScreen CRC Study Results
BRISBANE, Calif. | July 9, 2026 Freenome, an early cancer detection company advancing blood-based cancer screening technologies, has announced...
Johnson & Johnson’s RYBREVANT FASPRO Shows Strong HNSCC Results
CHICAGO, Illinois, May 31, 2026 Johnson & Johnson has reported pivotal results from the Phase 1b/2 OrigAMI-4 study, demonstrating...
Advertisements
GRAIL’s Galleri® Test Increases Cancer Detection 6.5-Fold in PATHFINDER 2 Study
MENLO PARK, California, May 31, 2026 GRAIL, Inc. has unveiled compelling new results from its registrational PATHFINDER 2 study,...
Gene Solutions Wins FDA Breakthrough Status for SPOT-MAS 10
SINGAPORE, May 28, 2026 Gene Solutions announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device...
Abbott Strengthens Leadership in CRC Screening
ABBOTT PARK, Ill., May 27, 2026 Abbott has announced that the updated American Cancer Society (ACS) colorectal cancer screening...
Nanostics AI ClarityDX Prostate Study Improves Cancer Detection
EDMONTON, Alberta, April 20, 2026 Nanostics Inc. has announced the publication of a peer-reviewed study validating its AI-powered ClarityDX®...
TOBY Gains FDA Breakthrough Status for MCED Test
AUSTIN, TEXAS, USA, April 14, 2026 TOBY, Inc. has received FDA Breakthrough Device Designation for its urine-based Multi-Cancer Early...
Advertisement
